• 国家药监局综合司 国家卫生健康委办公厅
  • 国家药监局综合司 国家卫生健康委办公厅

Effects of SGLT2 inhibitors on the metabolic syndrome and its components

Corresponding author: Zhang zhenwen, yzdxzzw@163.com
DOI: 10.12201/bmr.202503.00002
Statement: This article is a preprint and has not been peer-reviewed. It reports new research that has yet to be evaluated and so should not be used to guide clinical practice.
  •  

    Abstract: Metabolic syndrome is a group of interrelated risk factors and can be used as a predictor of diabetes and heart failure. Metabolic disorders such as insulin resistance, chronic oxidative stress, ectopic fat accumulation and abnormal regulation of lipid-related factors are the key components of metabolic syndrome. SGLT2 inhibitors are oral hypoglycemic agents that reduce blood glucose levels and induce body fat loss, which in turn improve the development of diabetic complications such as cardiovascular disease, Steatosis disease and chronic kidney disease. Insulin resistance plays a central role in metabolic syndrome and type 2 diabetes. It has been proved that SGLT2 inhibitor can improve insulin resistance through biochemical and neuroinhibitory pathways, such as glucose toxicity, lipotoxicity and oxidative stress, then reduce weight, regulate blood pressure, reduce blood sugar and improve blood lipids, play a role in regulating metabolism, heart and kidney protection

    Key words: SGLT2 inhibitors; metabolic syndrome; insulin resistance; cardio-renal-metabolic syndrome

    Submit time: 2 March 2025

    Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
  • 图表

  • Zhenghaijuan, NiuXiaohan. Research Progress of CCR and metabolic syndrome and its related diseases. 2025. doi: 10.12201/bmr.202501.00048

    Zhang Han, Chu Mengyuan, Xu Kaikai, Xiang Xin, Yan Ying. Progress in Mechanism of Action of Isthmin1 Protein in Polycystic Ovary Syndrome. 2024. doi: 10.12201/bmr.202411.00004

    Wangzhong. Correlation of Serum soluble TREM2 with Acute coronary syndrome in the elderly. 2024. doi: 10.12201/bmr.202412.00086

    XuHong. Advances in the treatment of osteopenia-seropathic obesity syndrome in the elderly. 2024. doi: 10.12201/bmr.202411.00064

    TANG Shishi, ZHOU Yi. Research on Hemorrhagic Fever with Renal Syndrome Incidence Prediction Based on the SARIMA-LSTM Model. 2024. doi: 10.12201/bmr.202407.00046

    shenyanqun, zhanglulu. Analysis on clinical features and prognostic factors in 68 adult hemophagocytic syndrome. 2025. doi: 10.12201/bmr.202502.00008

    YANG Xiaotong, LI Yifan, JI Wei. Visualization analysis of traditional Chinese medicine in the prevention and treatment of Sj?grens syndrome. 2025. doi: 10.12201/bmr.202502.00032

    Yang ShuJie, Zeng Ying, Yi HaiYing, Huang Jie, Gan Bin, Wei Xian, Tang Yanlin. Observation of the therapeutic effect of less invasive surfactant administration on respiratory distress syndrome in extremely premature infants. 2024. doi: 10.12201/bmr.202410.00018

    Zeng Wen-Mei, Zheng Yue, Li Yi-Min. Relationship of Human Neutrophil Peptides with the severity and prognosis of Acute Respiratory Distress Syndrome. 2024. doi: 10.12201/bmr.202410.00060

    王馨雨, ZHANG Shujuan. Research progress of GLP-2 in non-alcoholic fatty liver disease. 2025. doi: 10.12201/bmr.202502.00018

  • ID Submit time Number Download
    1 2024-12-28

    bmr.202503.00002V1

    Download
  • Public  Anonymous  To author only

Get Citation

Zhang zhenwen. Effects of SGLT2 inhibitors on the metabolic syndrome and its components. 2025. biomedRxiv.202503.00002

Article Metrics

  • Read: 42
  • Download: 0
  • Comment: 0

Email This Article

User name:
Email:*请输入正确邮箱
Code:*验证码错误